The World Health Organization (WHO) has launched the Integrated Drug Resistance Action Framework for HIV, hepatitis B and C, and sexually transmitted infections (STIs), covering the period from 2026 to 2030. This new framework serves as a critical roadmap to combat the escalating issue of drug resistance, which poses a significant threat to the progress made in addressing AIDS and the epidemics of hepatitis B, hepatitis C, and STIs.
Drug resistance has become a formidable challenge for public health. Without immediate and unified efforts, the rise in drug-resistant infections could result in more new cases, increased treatment failures, and ultimately higher rates of preventable illness and death. The WHO emphasizes that the emergence of drug resistance could jeopardize global efforts aimed at eliminating these health threats.
The framework outlines a comprehensive strategy designed to prevent the emergence and spread of drug resistance while reducing its overall impact. It focuses on five key strategic areas: prevention and response, monitoring and surveillance, research and innovation, laboratory capacity, and governance and enabling mechanisms.
Key Features of the Framework
Central to the framework is the concept of antimicrobial stewardship, which underscores the importance of responsible use of medications. It advocates for stronger surveillance systems and equitable access to high-quality prevention, diagnosis, and treatment services for HIV, hepatitis B, hepatitis C, and STIs.
Dr. Tereza Kasaeva, Director of WHO’s Department for HIV, Tuberculosis, Hepatitis, and Sexually Transmitted Infections, stated, “Drug resistance threatens decades of progress in HIV, hepatitis, and STI control. This framework is a call to action for countries, communities, and partners to unite around a shared agenda.” She emphasized that collaborative efforts are essential to maintain the effectiveness of life-saving antimicrobial drugs and to advance initiatives aimed at ending these epidemics.
The new framework aligns with WHO’s Global Health Sector Strategies and the Sustainable Development Goals. It also responds to the renewed political commitment following the 2024 UN High-level Meeting on Antimicrobial Resistance, providing a multisectoral roadmap for implementation.
As the world faces the growing challenge of drug resistance, the WHO’s Integrated Drug Resistance Action Framework represents a vital step towards safeguarding public health and ensuring continued progress in the fight against HIV, hepatitis B, hepatitis C, and STIs. Policymakers, healthcare providers, and communities are now called upon to adopt and implement these strategies to protect the health of populations globally.
